Page last updated: 2024-12-10

s 145

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S 145: TXA2/PGH2 receptor antagonist; RN given refers to (+)-isomer; RN for cpd without isomeric designation not available 10/88; S-1452 is the calcium hydrate form of S-145 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5312138
CHEMBL ID3301671
CHEBI ID135586
SCHEMBL ID361563
SCHEMBL ID361564
MeSH IDM0158635

Synonyms (36)

Synonym
gtpl1984
[3h]s-145
(z)-7-[(1r,4s,5s,6s)-5-(phenylsulfonylamino)-6-bicyclo[2.2.1]heptanyl]hept-5-enoic acid
gtpl1979
(+)-s-145
s-1452 ,
S-145 ,
5-heptenoic acid, 7-((1r,2s,3s,4s)-3-((phenylsulfonyl)amino)bicyclo(2.2.1)hept-2-yl)-, (5z)-
(+)-(z)-7-((1r,2s,3s,4s)-3-benzenesulfonamido-2-norbornyl)-5-heptenoic acid
calcium 5,7-(3-phenylsulfonylaminobicyclo(2.2.1)hept-2-yl)-5-heptenoate hydrate
5,7-(3-phenylsulfonylamino(2.2.1)bicyclohept-2-yl)heptenoic acid
5-heptenoic acid, 7-(3-((phenylsulfonyl)amino)bicyclo(2.2.1)hept-2-yl)-, (1r-(1alpha,2alpha(z),3beta,4alpha))-
domitroban
s 145
CHEBI:135586
(z)-7-[(1r,2s,3s,4s)-3-(benzenesulfonamido)-2-bicyclo[2.2.1]heptanyl]hept-5-enoic acid
112966-96-8
742f5k270q ,
domitroban [inn]
unii-742f5k270q
(+/-)-s-145
6c4w5d1se7 ,
domitroban, (+/-)-
domitroban (+/-)-form [mi]
5-heptenoic acid, 7-((1r,2s,3s,4s)-3-((phenylsulfonyl)amino)bicyclo(2.2.1)hept-2-yl)-, (5z)-rel-
unii-6c4w5d1se7
7-(3-((phenylsulfonyl)amino)bicyclo(2.2.1)hept-2-yl)-5-heptenoic acid, (+/-)-(5z)-
s-145 (thromboxane antagonist)
115266-92-7
domitroban [mi]
CHEMBL3301671
SCHEMBL361563
SCHEMBL361564
(1r,2s,3s,4s)-(5z)-7-(3-((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoic acid
Q27077097
DTXSID401318399

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The present study was undertaken to determine whether nocturnal dosage with S-1452, a thromboxane A2 receptor antagonist, would blunt the morning rise in platelet aggregability."( Effect of treatment at night with S-1452, a thromboxane A2 receptor antagonist, on the morning rise in platelet aggregation.
Ebihara, A; Fujimura, A; Kumagai, K; Ohashi, K, 1992
)
0.28
" While pretreatment with inhaled AS-35 (1mg) did not affect the STA2 dose-response curve."( Interaction of thromboxane A2 and leukotrienes in guinea pig airways in vivo.
Bando, T; Fujimura, M; Matsuda, T; Mizuhashi, K, 1991
)
0.28
"9 h after dosing with food."( Effect of food intake on pharmacokinetics and effects of a new thromboxane A2 receptor antagonist, S-1452.
Ebihara, A; Fujimura, A; Kotegawa, T; Kumagai, Y; Ohashi, K; Shiga, T, 1996
)
0.29
"These results suggest that although the absorption of S-1452 is delayed and, consequently, its plasma concentration is decreased after dosing with food, the inhibitory effect on platelet aggregation is not significantly influenced after 50 mg of the drug."( Effect of food intake on pharmacokinetics and effects of a new thromboxane A2 receptor antagonist, S-1452.
Ebihara, A; Fujimura, A; Kotegawa, T; Kumagai, Y; Ohashi, K; Shiga, T, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1346422Human TP receptor (Prostanoid receptors)1991Nature, Feb-14, Volume: 349, Issue:6310
Cloning and expression of cDNA for a human thromboxane A2 receptor.
AID1346405Mouse TP receptor (Prostanoid receptors)1992Biochemical and biophysical research communications, May-15, Volume: 184, Issue:3
Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis.
AID1346422Human TP receptor (Prostanoid receptors)1991British journal of pharmacology, Aug, Volume: 103, Issue:4
Kinetic studies on stereospecific recognition by the thromboxane A2/prostaglandin H2 receptor of the antagonist, S-145.
AID1346405Mouse TP receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (97)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (15.46)18.7374
1990's71 (73.20)18.2507
2000's10 (10.31)29.6817
2010's1 (1.03)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.90 (24.57)
Research Supply Index4.66 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index171.59 (26.88)
Search Engine Supply Index3.97 (0.95)

This Compound (53.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (3.96%)5.53%
Reviews1 (0.99%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other96 (95.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]